• 1. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 4. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 5. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Oligosaccharides
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Oligosaccharides

Comprehensive Guide to Betadex Sulfobutyl Ether Sodium (CAS No. 182410-00-0): Properties, Applications, and Market Insights

Betadex Sulfobutyl Ether Sodium, also known as Sulfobutylether-β-Cyclodextrin Sodium (SBECD), is a chemically modified cyclodextrin derivative with the CAS number 182410-00-0. This compound has gained significant attention in the pharmaceutical and biotechnology industries due to its unique properties as a solubility enhancer and stabilizer. With the increasing demand for advanced drug delivery systems, SBECD has become a critical excipient in formulations for poorly water-soluble drugs.

The molecular structure of Betadex Sulfobutyl Ether Sodium consists of a β-cyclodextrin backbone substituted with sulfobutyl ether groups, which are negatively charged at physiological pH. This modification enhances its water solubility and reduces renal toxicity compared to native cyclodextrins. Researchers and formulators often search for "SBECD solubility enhancement" or "Betadex Sulfobutyl Ether Sodium in drug delivery" to understand its mechanisms of action, which include forming inclusion complexes with hydrophobic drug molecules.

One of the most prominent applications of Betadex Sulfobutyl Ether Sodium is in the formulation of injectable drugs. Its ability to improve the solubility of lipophilic compounds while maintaining low toxicity makes it ideal for parenteral formulations. Current trends show growing interest in "SBECD for mRNA vaccines" and "Betadex Sulfobutyl Ether Sodium in biopharmaceuticals," reflecting its potential in cutting-edge therapeutic areas. The compound's safety profile has been well-established through numerous studies, making it a preferred choice for regulatory-approved formulations.

The pharmaceutical industry is increasingly adopting Sulfobutylether-β-Cyclodextrin Sodium as a versatile excipient. Market analysis reveals rising searches for "SBECD manufacturers" and "Betadex Sulfobutyl Ether Sodium price," indicating growing commercial interest. The global market for cyclodextrin derivatives is projected to expand significantly, driven by the demand for advanced drug delivery solutions and biopharmaceutical formulations. Quality parameters such as "SBECD purity standards" and "Betadex Sulfobutyl Ether Sodium specifications" are critical considerations for pharmaceutical companies.

From a regulatory perspective, Betadex Sulfobutyl Ether Sodium has been approved by major health authorities worldwide for use in various drug products. Researchers frequently inquire about "SBECD regulatory status" and "Betadex Sulfobutyl Ether Sodium safety data," highlighting the importance of compliance in pharmaceutical applications. The compound's monograph is included in major pharmacopeias, ensuring standardized quality for global pharmaceutical use. Recent advancements in analytical methods for characterizing SBECD have further strengthened its position in the industry.

Beyond traditional pharmaceutical applications, Sulfobutylether-β-Cyclodextrin Sodium shows promise in emerging fields. There's growing interest in its potential for "SBECD in gene therapy" and "Betadex Sulfobutyl Ether Sodium for protein stabilization." These applications leverage the compound's ability to protect sensitive biological molecules from degradation while improving their delivery efficiency. The scientific community continues to explore novel uses of SBECD, particularly in advanced therapeutic medicinal products (ATMPs) and personalized medicine approaches.

Quality control of Betadex Sulfobutyl Ether Sodium remains a crucial aspect for manufacturers and end-users. Common search queries include "SBECD analytical methods" and "Betadex Sulfobutyl Ether Sodium testing protocols," reflecting the need for robust characterization techniques. Modern analytical approaches such as mass spectrometry and advanced chromatographic methods are employed to ensure batch-to-batch consistency and compliance with stringent pharmaceutical standards.

The environmental profile of Sulfobutylether-β-Cyclodextrin Sodium has also become a subject of interest, with searches for "SBECD biodegradability" and "Betadex Sulfobutyl Ether Sodium environmental impact" increasing. Studies indicate that SBECD exhibits favorable environmental characteristics compared to many synthetic excipients, aligning with the pharmaceutical industry's growing emphasis on green chemistry principles.

Looking ahead, the future of Betadex Sulfobutyl Ether Sodium appears promising as research continues to uncover new applications. The compound's versatility in addressing formulation challenges for new chemical entities and biologics positions it as a valuable tool in drug development. With ongoing innovations in drug delivery technologies and the expanding biopharmaceutical market, SBECD is poised to play an increasingly important role in modern therapeutics.

• 141186-39-2(1-Butanesulfonic acid, 4-[(2-decyl-2-methyl-1,3-dioxolan-4-yl)methoxy]-, sodium salt (1:1))
• 308818-13-5(3-(2-Methyl-2-undecyl-1,3-dioxolane-4-ylmethoxy)-1-propanesulfonic acid sodium salt)
• 308818-10-2(1-Butanesulfonic acid, 4-[(2-methyl-2-undecyl-1,3-dioxan-5-yl)oxy]-)
• 2308-53-4(a-D-Glucopyranoside,2,3-dihydroxypropyl 6-deoxy-6-sulfo-)
• 923600-60-6(4,7,11,14-Tetraoxaheptadecane-1,17-disulfonic acid, 5,13-didodecyl-, sodium salt (1:2))
• 88244-36-4(6-Sulfo-6-desoxy-alpha-D-glucopyranosyl-(1,1')-D-glycerol)
• 308818-11-3(1-Propanesulfonic acid,3-[(2-methyl-2-undecyl-1,3-dioxolan-4-yl)methoxy]-)
• 906340-43-0(6-Sulfo-chinovose-glycerin)
• 165133-56-2(Heptakis-O-(4-sulfobutyl)-beta-Cyclodextrin)
• 108699-84-9(β-Cyclodextrin, 6A-deoxy-6A-sulfo-)